$0.71
Value $6.1M
NHTC and TSLA stock compared: price, dividend, valuation and results, from SEC filings.
$0.71
Value $6.1M
$379.74
Value $1.50T
Natural Health Trends (NHTC) has a market value of $6.1M and Tesla (TSLA) $1.50T. Over the last year, with dividends, NHTC moved -77.7% and TSLA -6.1%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
NHTC$6.1M
TSLA$1.50T
TSLA is 245,770 times NHTC
Revenue, 12 months
NHTC$34M
TSLA$104B
TSLA is 3,036 times NHTC
Net income, 12 months
NHTC-$1.4M
TSLA$3.2B
Operating margin
NHTC-5.9%
TSLA3.4%
9.3 points apart
ROIC
NHTC-8.3%
TSLA2.9%
11.2 points apart
P/E
NHTC–
TSLA466.5
Dividend yield
NHTC0.0%
TSLA0.0%
About the same
5-year return
NHTC-82.7%
TSLA+12.4%
95.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
NHTC-82.7%
TSLA+12.4%
| Period | NHTCWith dividends | TSLAWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -77.7%Price -80.3% | -6.1%Price -6.1% |
| 3 years since November 16, 2023 | -80.9%-42.4% a yearPrice -86.8% | +62.6%+17.6% a yearPrice +62.6% |
| 5 years since November 15, 2021 | -82.7%-29.6% a yearPrice -91.0% | +12.4%+2.4% a yearPrice +12.4% |
| 10 years since November 17, 2016 | -91.1%-21.5% a yearPrice -97.2% | +2,918.6%+40.6% a yearPrice +2,918.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
NHTCNatural Health TrendsTSLATesla
| Price | $0.71 | $379.74 |
|---|---|---|
| Market value | $6.1M | $1.50T |
| Enterprise value (EV) | – | $1.47T |
| P/E | – | 466.5 |
| P/E, 5-year median | – | – |
| P/B | 0.4 | 16.8 |
| EV/EBIT | – | 422.7 |
| Free cash flow yield | – | 0.2% |
| Revenue, 12 months | $34M | $104B |
|---|---|---|
| Net income, 12 months | -$1.4M | $3.2B |
| Free cash flow, 12 months | -$4.7M | $3.3B |
| Earnings per share, 12 months | -$0.15 | $0.91 |
| Revenue growth, year on year | -7.4% | -2.9% |
| Revenue growth a year, past | -8.5%over 5 years | +24.6%over 5 years |
| EPS growth a year, past | – | +38.8%over 5 years |
| Gross margin | 74.3% | 19.3% |
|---|---|---|
| Operating margin | -5.9% | 3.4% |
| Net margin | -4.2% | 3.1% |
| ROIC | -8.3% | 2.9% |
| ROE | -7.4% | 3.8% |
| Cash | $18M | $45.4B |
|---|---|---|
| Total debt | $2.6M | $16.4B |
| Net debt / EBITDA | – | -4.2 |
| Interest cover | – | 10.0× |
| Dividend yield | – | – |
|---|---|---|
| Dividend per share, 12 months | $0.60 | – |
| Dividend growth a year, past | +0.0%over 5 years | – |
| Buyback yield | – | – |
| Shareholder yield | 84.3% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Tesla ($1.50T) is about 245,769.6 times Natural Health Trends ($6.1M), at today's prices.
Since November 17, 2016, NHTC's price moved -97.2% and TSLA's +2,918.6%. With dividends: NHTC -91.1% (-21.5% a year), TSLA +2,918.6% (+40.6% a year). Past returns do not predict future ones.
Neither paid a dividend over the last twelve months: Natural Health Trends and Tesla return money to shareholders, if they do, in other ways, such as buybacks.
Over the last twelve months, the net margin was -4.2% for Natural Health Trends and 3.1% for Tesla, and the operating margin -5.9% and 3.4%. Revenue was $34M and $104B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.